Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease is a dataset published in New England Journal of Medicine (2021). On theSindex it has a DataRank of 6.5, placing it in the top 2.9% of the data-sharing corpus. It has been cited 1,083 times, with 100 citing works in its 1-hop citation network.
Ranks in the top 3% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
1.0
From this paper's citation signal
Citation Network Contribution
5.4
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institutes of Health
Grant: 2U01DK061738-19
Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
National Institutes of Health
Grant: 3UL1TR000100-05S2
San Diego Clinical and Translational Research Institute
National Institutes of Health
Grant: 3UL1TR000423-07S1
Institute of Translational Health Sciences
National Institutes of Health
Grant: 2UL1TR000436-06A1
Duke CTSA
National Institutes of Health
Grant: 5UL1TR000004-10
Clinical and Translational Science Institute
National Institutes of Health
Grant: 8UL1TR000006-05
Indiana Clinical and Translational Science Institute (UL1)
National Institutes of Health
Grant: 3U01DK061734-14S2
Clinical Research on Nonalcoholic Fatty Liver Disease
National Institutes of Health
Grant: 2U01DK061713-18
Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
National Institutes of Health
Grant: 4UL1TR000448-10
Washington University Institute of Clinical and Translational Sciences
National Institutes of Health
Grant: 5UL1TR002649-02
Center for Clinical and Translational Research
National Institutes of Health
Grant: 1U01DK061730-01
Clinical Research Network in Non-Alcoholic Steatohepati*
National Institutes of Health
Grant: 2UL1TR000439-06
Clinical and Translational Science Collaborative of Cleveland
National Institutes of Health
Grant: 3U01DK061737-11S2
Collaborative Clinical Research on Non Alcoholic Stratohepatitis
National Institutes of Health
Grant: 5U01DK061728-08
Clinical Research Network in Non Alcoholic Steatohepatitis
National Institutes of Health
Grant: 5U01DK061718-22
The Saint Louis University Component of the NASH CRN
National Institutes of Health
Grant: 3U01DK061731-11S1
Nonalcoholic Steatohepatitis Clinical Research Network
National Institutes of Health
Grant: 5U01DK061732-04
NASH PROJECT
Fields of Study
Keywords
Sustainable Development Goals
Additional file 2 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Additional file 2 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Additional file 1 of Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
Additional file 1 of Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
Additional file 1 of Prevalence of overweight/obesity and its relationship with metabolic syndrome and fatty liver index in adult patients with type 1 diabetes. A Brazilian multicenter study
Additional file 1 of Prevalence of overweight/obesity and its relationship with metabolic syndrome and fatty liver index in adult patients with type 1 diabetes. A Brazilian multicenter study
Additional file 3 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Additional file 3 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Additional file 4 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Additional file 4 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Additional file 2 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 1 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 4 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 4 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 1 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 3 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 3 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 2 of Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
Additional file 1 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank
Additional file 1 of Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank